Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kim, Ju Hee ^a   Park, Jae Myung ^a,c   Roh, Yoon Jin ^a   Kim, In Wook ^a   Hasan, Tayyaba ^b   Choi, Myung Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c The Catholic University of Korea   (South Korea)

Author keywords

ATP binding cassette transporters; Colon cancer; Photodynamic therapy; Photosensitizing agents; Protoporphyrin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MESSENGER RNA; PHOTOSENSITIZING AGENT; PYROPHEOPHORBID A; SINGLET OXYGEN; UNCLASSIFIED DRUG; 3-(6-ISOBUTYL-9-METHOXY-1,4-DIOXO-1,2,3,4,6,7,12,12A-OCTAHYDROPYRAZINO(1',2'-1,6)PYRIDO(3,4-B)INDOL-3-YL)PROPIONIC ACID TERT-BUTYL ESTER; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ADENOSINE; FUSED HETEROCYCLIC RINGS; PIPERAZINEDIONE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL SURVIVAL; CELL VIABILITY; CLINICAL EFFECTIVENESS; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; HT 29 CELL LINE; IN VITRO STUDY; INCUBATION TIME; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOTOXICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SW480 CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DISEASE MODEL; DRUG SCREENING; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

ADENOSINE; ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIKETOPIPERAZINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MALE; MICE; NEOPLASM PROTEINS; PHOTOCHEMOTHERAPY; RNA, MESSENGER; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84935426678     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1514-4     Document Type: Article

References (27)

1. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380-7.
2. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535-45.
3. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002;1(1):1-21.
4. Choudhary S, Nouri K, Elsaie ML. Photodynamic therapy in dermatology: a review. Lasers Med Sci. 2009;24(6):971-80.
5. Tang PM, Liu XZ, Zhang DM, Fong WP, Fung KP. Pheophorbide a based photodynamic therapy induces apoptosis via mitochondrial-mediated pathway in human uterine carcinosarcoma. Cancer Biol Ther. 2009;8(6):533-9.
6. Chan JY, Tang PM, Hon PM, Au SW, Tsui SK, Waye MM, et al. Pheophorbide a, a major antitumor component purified from Scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells. Planta Med. 2006;72(1):28-33.
7. Yin X, Zhou J, Jie C, Xing D, Zhang Y. Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci. 2004;75(18):2233-44.
8. Nakamura Y, Murakami A, Koshimizu K, Ohigashi H. Inhibitory effect of pheophorbide a, a chlorophyll-related compound, on skin tumor promotion in ICR mouse. Cancer Lett. 1996;108(2):247-55.
9. Lee WY, Lim DS, Ko SH, Park YJ, Ryu KS, Ahn MY, et al. Photoactivation of pheophorbide a induces a mitochondrial-mediated apoptosis in Jurkat leukaemia cells. J Photochem Photobiol B. 2004;75(3):119-26.
10. Hajri A, Wack S, Meyer C, Smith MK, Leberquier C, Kedinger M, et al. In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells. Photochem Photobiol. 2002;75(2):140-8.
11. Jin ZH, Miyoshi N, Ishiguro K, Umemura S, Kawabata K, Yumita N, et al. Combination effect of photodynamic and sonodynamic therapy on experimental skin squamous cell carcinoma in C3H/HeN mice. J Dermatol. 2000;27(5):294-306.
12. Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther. 2005;4(2):187-94.
13. Ishikawa T, Nakagawa H, Hagiya Y, Nonoguchi N, Miyatake S, Kuroiwa T. Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. Adv pharmacol Sci. 2010;2010:587306.
14. Krishnamurthy P, Xie T, Schuetz JD. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther. 2007;114(3):345-58.
15. Wakabayashi K, Tamura A, Saito H, Onishi Y, Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab Rev. 2006;38(3):371-91.
16. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 2002;99(24):15649-54.
17. Wang X, Xia B, Liang Y, Peng L, Wang Z, Zhuo J, et al. Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival. Cancer Biomark. 2013;13(2):81-8.
18. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002;1(6):417-25.
19. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376(6535):37-43.
20. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005;12 Suppl 2:1509-18.
21. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
22. Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011;10(7):1252-63.
23. Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers. 2011;3(2):2516-39.
24. Sackova V, Kulikova L, Mikes J, Kleban J, Fedorocko P. Hypericin-mediated photocytotoxic effect on HT-29 adenocarcinoma cells is reduced by light fractionation with longer dark pause between two unequal light doses. Photochem Photobiol. 2005;81(6):1411-6.
25. Choi BH, Ryoo IG, Kang HC, Kwak MK. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One. 2014;9(9), e107158.
26. Jendzelovsky R, Mikes J, Koval J, Soucek K, Prochazkova J, Kello M, et al. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009;8(12):1716-23.
27. Jung KA, Choi BH, Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 2015;87(3):465-76.